New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
07:10 EDTCLDNCelladon announces in-license of stem cell factor development program
Celladon announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene, or mSCF, for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to cell migration, proliferation, and survival of cardiac stem cells. Researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai have successfully tested mSCF gene therapy to reverse heart damage following myocardial infarction in animal models. Celladon plans to commence further preclinical work, building on available data from Mount Sinai in myocardial infarction.
News For CLDN From The Last 14 Days
Check below for free stories on CLDN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CLDN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use